|
1
|
Ueda SM, Mao TL, Kuhajda FP, Vasoontara C,
Giuntoli RL, Bristow RE, Kurman RJ and Shih IeM: Trophoblastic
neoplasms express fatty acid synthase, which may be a therapeutic
target via its inhibitor C93. Am J Pathol. 175:2618–2624. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wadhwa R, Song S, Lee JS, Yao Y, Wei Q and
Ajani JA: Gastric cancer-molecular and clinical dimensions. Nat Rev
Clin Oncol. 10:643–655. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Qian J, Qian Y, Wang J, Gu B, Pei D, He S,
Zhu F, Røe OD, Xu J, Liu L, et al: A clinical prognostic scoring
system for resectable gastric cancer to predict survival and
benefit from paclitaxel-or oxaliplatin-based adjuvant chemotherapy.
Drug Des Devel Ther. 10:241–258. 2016.PubMed/NCBI
|
|
4
|
Lordick F, Allum W, Carneiro F, Mitry E,
Tabernero J, Tan P, Van Cutsem E, van de Velde C and Cervantes A:
Unmet needs and challenges in gastric cancer: The way forward.
Cancer Treat Rev. 40:692–700. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fernandez-Marrero Y, Spinner S, Kaufmann T
and Jost PJ: Survival control of malignant lymphocytes by
anti-apoptotic MCL-1. Leukemia. 30:2152–2159. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Perini GF, Ribeiro GN, Neto Pinto JV,
Campos LT and Hamerschlak N: BCL-2 as therapeutic target for
hematological malignancies. J Hematol Oncol. 11:652018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Huang XL, Cui GH and Zhou KY: Correlation
of PI3K-Akt signal pathway to apoptosis of tumor cells. Ai Zheng.
27:331–336. 2008.(In Chinese). PubMed/NCBI
|
|
8
|
Urrutia R: The IAP: More international
than ever. Pancreatology. 9:III–IV. 2009. View Article : Google Scholar
|
|
9
|
Liu JL, Gao W, Kang QM, Zhang XJ and Yang
SG: Prognostic value of survivin in patients with gastric cancer: A
systematic review with meta-analysis. PLoS One. 8:e719302013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim MA, Lee HE, Lee HS, Yang HK and Kim
WH: Expression of apoptosis-related proteins and its clinical
implication in surgically resected gastric carcinoma. Virchows
Arch. 459:503–510. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang X, Beitler JJ, Huang W, Chen G, Qian
G, Magliocca K, Patel MR, Chen AY, Zhang J, Nannapaneni S, et al:
Honokiol radiosensitizes squamous cell carcinoma of the head and
neck by downregulation of survivin. Clin Cancer Res. 24:858–869.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
O'Connor DS, Wall NR, Porter AC and
Altieri DC: A p34(cdc2) survival checkpoint in cancer. Cancer Cell.
2:43–54. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Werner TA, Tamkan-Olcek Y, Dizdar L,
Riemer JC, Wolf A, Cupisti K, Verde PE, Knoefel WT and Krieg A:
Survivin and XIAP: Two valuable biomarkers in medullary thyroid
carcinoma. Br J Cancer. 114:427–434. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ambrosini G, Adida C and Altieri DC: A
novel anti-apoptosis gene, survivin, expressed in cancer and
lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Singh N, Krishnakumar S, Kanwar RK, Cheung
CH and Kanwar JR: Clinical aspects for survivin: A crucial molecule
for targeting drug-resistant cancers. Drug Discov Today.
20:578–587. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bi Y, Zhang Y, Cui C, Ren L and Jiang X:
Gene-silencing effects of anti-survivin siRNA delivered by
RGDV-functionalized nanodiamond carrier in the breast carcinoma
cell line MCF-7. Int J Nanomedicine. 11:5771–5787. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jia Y, Hu R, Li P, Zheng Y, Wang Y and Ma
X: DEC1 is required for anti-apoptotic activity of gastric cancer
cells under hypoxia by promoting Survivin expression. Gastric
Cancer. 2017.(Epub Ahead of Print).
|
|
18
|
Tsuburaya A, Noguchi Y, Yoshikawa T, Saito
A, Doi C, Okamoto T and Fukuzawa K: An anti-apoptosis gene,
survivin and telomerase expression in gastric cancer.
Hepatogastroenterology. 49:1150–1152. 2002.PubMed/NCBI
|
|
19
|
Li YH, Wang C, Meng K, Chen LB and Zhou
XJ: Influence of survivin and caspase-3 on cell apoptosis and
prognosis in gastric carcinoma. World J Gastroenterol.
10:1984–1988. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang XY, Wang MW, Wang GS and You WD:
Expression of human anti-apoptotic gene survivin and its splice in
normal human gastric tissue and gastric cancer. Zhonghua Yi Xue Yi
Chuan Xue Za Zhi. 20:75–76. 2003.(In Chinese). PubMed/NCBI
|
|
21
|
Cao W, Yang W, Li H, Lou G, Jiang J, Geng
M, Xi W, Ren R, Qu Q, Jin X, et al: Using detection of
survivin-expressing circulating tumor cells in peripheral blood to
predict tumor recurrence following curative resection of gastric
cancer. J Surg Oncol. 103:110–115. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liston P, Roy N, Tamai K, Lefebvre C,
Baird S, Cherton-Horvat G, Farahani R, McLean M, Ikeda JE,
MacKenzie A and Korneluk RG: Suppression of apoptosis in mammalian
cells by NAIP and a related family of IAP genes. Nature.
379:349–353. 1996. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hunter AM, LaCasse EC and Korneluk RG: The
inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis.
12:1543–1568. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang DG, Sun YB, Ye F, Li W, Kharbuja P,
Gao L, Zhang DY and Suo J: Anti-tumor activity of the X-linked
inhibitor of apoptosis (XIAP) inhibitor embelin in gastric cancer
cells. Mol Cell Biochem. 386:143–152. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Suzuki Y, Imai Y, Nakayama H, Takahashi K,
Takio K and Takahashi R: A serine protease, HtrA2, is released from
the mitochondria and interacts with XIAP, inducing cell death. Mol
Cell. 8:613–621. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dohi T, Okada K, Xia F, Wilford CE, Samuel
T, Welsh K, Marusawa H, Zou H, Armstrong R, Matsuzawa S, et al: An
IAP-IAP complex inhibits apoptosis. J Biol Chem. 279:34087–34090.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bamboat ZM, Tang LH, Vinuela E, Kuk D,
Gonen M, Shah MA, Brennan MF, Coit DG and Strong VE:
Stage-stratified prognosis of signet ring cell histology in
patients undergoing curative resection for gastric adenocarcinoma.
Ann Surg Oncol. 21:1678–1685. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Singh S, Narang AS and Mahato RI:
Subcellular fate and off-target effects of siRNA, shRNA, and miRNA.
Pharm Res. 28:2996–3015. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kaur IP, Chopra K, Rishi P, Puri S and
Sharma G: Small RNAs: The qualified candidates for gene
manipulation in diverse clinical pathologies. Crit Rev Ther Drug
Carrier Syst. 31:305–329. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xuan Q, Ji H, Tao X, Xu Y and Zhang Q:
Quantitative assessment of HER2 amplification in HER2-positive
breast cancer: Its association with clinical outcomes. Breast
Cancer Res Treat. 150:581–588. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu S, Zhang W, Liu K, Wang Y, Ji B and
Liu Y: Synergistic effects of co-expression plasmidbased
ADAM10-specific siRNA and GRIM-19 on hepatocellular carcinoma in
vitro and in vivo. Oncol Rep. 32:2501–2510. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fulda S: Inhibitor of Apoptosis (IAP)
proteins in hematological malignancies: Molecular mechanisms and
therapeutic opportunities. Leukemia. 28:1414–1422. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chene P: Inhibiting the p53-MDM2
interaction: An important target for cancer therapy. Nat Rev
Cancer. 3:102–109. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rajalingam K, Sharma M, Paland N, Hurwitz
R, Thieck O, Oswald M, Machuy N and Rudel T: IAP-IAP complexes
required for apoptosis resistance of C. Trachomatis-infected cells.
PLoS Pathog. 2:e1142006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hatakeyama K, Yamakawa Y, Fukuda Y,
Ohshima K, Wakabayashi-Nakao K, Sakura N, Tanizawa Y, Kinugasa Y,
Yamaguchi K, Terashima M and Mochizuki T: A novel splice variant of
XIAP-associated factor 1 (XAF1) is expressed in peripheral blood
containing gastric cancer-derived circulating tumor cells. Gastric
Cancer. 18:751–761. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Arora V, Cheung HH, Plenchette S, Micali
OC, Liston P and Korneluk RG: Degradation of survivin by the
X-linked inhibitor of apoptosis (XIAP)-XAF1 complex. J Biol Chem.
282:26202–26209. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hehlgans S, Petraki C, Reichert S, Cordes
N, Rodel C and Rodel F: Double targeting of Survivin and XIAP
radiosensitizes 3D grown human colorectal tumor cells and decreases
migration. Radiother Oncol. 108:32–39. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yang J, Ouyang J, Ouyang L and Chen Y:
Inhibition of cell proliferation and increase of chemosensitivity
by simultaneous knockdown of XIAP and survivin in pancreatic
carcinoma cells. Oncol Res. 21:43–50. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lee SH, Lee JY, Jung CL, Bae IH, Suh KH,
Ahn YG, Jin DH, Kim TW, Suh YA and Jang SJ: A novel antagonist to
the inhibitors of apoptosis (IAPs) potentiates cell death in
EGFR-overexpressing non-small-cell lung cancer cells. Cell Death
Dis. 5:e14772014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
de Moraes Nestal G, Delbue D, Silva KL,
Robaina MC, Khongkow P, Gomes AR, Zona S, Crocamo S, Mencalha AL,
Magalhães LM, et al: FOXM1 targets XIAP and Survivin to modulate
breast cancer survival and chemoresistance. Cell Signal.
27:2496–2505. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chawla-Sarkar M, Bae SI, Reu FJ, Jacobs
BS, Lindner DJ and Borden EC: Downregulation of Bcl-2, FLIP or IAPs
(XIAP and survivin) by siRNAs sensitizes resistant melanoma cells
to Apo2L/TRAIL-induced apoptosis. Cell Death Differ. 11:915–923.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Krepela E, Dankova P, Moravcikova E,
Krepelova A, Prochazka J, Cermak J, Schützner J, Zatloukal P and
Benkova K: Increased expression of inhibitor of apoptosis proteins,
survivin and XIAP, in non-small cell lung carcinoma. Int J Oncol.
35:1449–1462. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yang D, Song X, Zhang J, Ye L, Wang S, Che
X, Wang J, Zhang Z, Wang L and Shi W: Therapeutic potential of
siRNA-mediated combined knockdown of the IAP genes (Livin, XIAP,
and Survivin) on human bladder cancer T24 cells. Acta Biochim
Biophys Sin (Shanghai). 42:137–144. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yi XP, Han T, Li YX, Long XY and Li WZ:
Simultaneous silencing of XIAP and survivin causes partial
mesenchymal-epithelial transition of human pancreatic cancer cells
via the PTEN/PI3K/Akt pathway. Mol Med Rep. 12:601–608. 2015.
View Article : Google Scholar : PubMed/NCBI
|
